Inclisiran API is a pharmaceutical-grade small interfering RNA (siRNA) therapeutic designed to reduce low-density lipoprotein cholesterol (LDL-C) by selectively inhibiting the production of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the liver. By suppressing PCSK9 synthesis, Inclisiran increases LDL receptor availability, leading to enhanced clearance of LDL cholesterol from the bloodstream.
Inclisiran is indicated for the treatment of primary hypercholesterolemia, mixed dyslipidemia, and patients with atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C reduction. Its long-lasting mechanism allows infrequent dosing while maintaining effective cholesterol control.
Manufactured under WHO-GMP-certified facilities, our Inclisiran API is produced using advanced oligonucleotide manufacturing technology to ensure exceptional purity, biological activity, stability, and batch-to-batch consistency. Every batch is supplied with complete regulatory documentation including Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and Product Specifications.
Inclisiran API is used in injectable pharmaceutical formulations for lowering LDL cholesterol in patients with primary hypercholesterolemia, mixed dyslipidemia, and atherosclerotic cardiovascular disease.
Inclisiran uses RNA interference (RNAi) technology to inhibit hepatic PCSK9 production, increasing LDL receptor expression and enhancing LDL cholesterol clearance from the bloodstream.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation with every shipment.
Yes. We supply Inclisiran API in commercial quantities for pharmaceutical and biopharmaceutical manufacturing with worldwide export support.
Get Bulk Quote via WhatsApp